Format

Send to

Choose Destination
Vaccine. 2017 Jan 5;35(2):208-211. doi: 10.1016/j.vaccine.2016.11.076. Epub 2016 Dec 5.

Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.

Author information

1
School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, England, United Kingdom. Electronic address: hannah.christensen@bristol.ac.uk.
2
Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, England, United Kingdom. Electronic address: clt56@cam.ac.uk.

Abstract

We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive because of declining disease burden. We estimate catch-up vaccination of 1year old children could be cost-effective, incremental on the infant programme with a vaccine price of ⩽£8 per dose. Extending vaccination to 2year olds could only be cost-effective (incremental on infant and 1year old catch-up) with a vaccine price of ⩽£3 per dose and was not cost-effective in sensitivity analyses with more conservative vaccine assumptions. Extending catch-up further to 3-4year olds was not cost-effective. Employing the current criteria for assessing vaccines, our models suggest that even with low vaccine prices only catch-up vaccination in 1year old children could be cost-effective, when considered incrementally on the infant programme.

KEYWORDS:

Catch-up; Cost-effectiveness; Group B; Meningococcal disease; Vaccination

PMID:
27923519
PMCID:
PMC5418563
DOI:
10.1016/j.vaccine.2016.11.076
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center